Legal Weed Expansion Tied to Rise in Heart Attack Hospitalizations

Nearly half of U.S. states have legalized recreational cannabis, opening the door to widespread availability and normal consumer access. However, a newly published study points toward a potentially serious public health trade-off: a statistical rise in cardiovascular problems following legalization. Researchers based in Boston examined hospitalization data across the country to understand how early adoption of recreational pot affected regional health outcomes.

The investigative team analyzed records from the National Inpatient Sample, focusing heavily on the western census region where states like Colorado, Washington, and California first established legal markets between 2014 and 2018. Before legalization took effect, hospitalization rates for cardiovascular diseases in the western states generally sat lower than the national average. Yet, data revealed that those rates began accelerating more rapidly after 2014, outpacing regions without legal recreational sales.

After controlling for various external factors, the researchers calculated a statistically significant correlation between the duration of legal cannabis and specific heart complications. For every year recreational cannabis remained legal in a western state, rates of atrial fibrillation, heart failure, and heart attacks climbed by roughly 2 percent, 4 percent, and 3 percent respectively. To validate these trends, the study tracked unrelated medical conditions like urinary stones, which remained entirely stable over the same timeframe.

While the observational nature of the research demonstrates correlation rather than definitive causation, the findings offer a novel population-level perspective that moves beyond individual surveys. The authors suggest that policymakers take a cautious approach to future expansions and advocate for reclassifying cannabis to a Schedule III drug. Such a regulatory shift would simplify clinical research, allowing scientists to pinpoint which specific compounds or consumption methods drive these cardiovascular risks.